OncoSil Medical (ASX:OSL) YoY EBITDA Growth: 66.67% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:OSL OncoSil Medical Ltd ASX:OSL
40 GF Score
Price A$1.11
GF Value A$2.91
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is OncoSil Medical YoY EBITDA Growth?

OncoSil Medical ASX:OSL +7.77% 40 YoY EBITDA Growth is 66.67% as of Dec. 2025. GuruFocus rates ASX:OSL with a GF Score™ of 40/100 and a GF Value™ of A$2.91 (Possible Value Trap). The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. OncoSil Medical's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 66.67%.

OncoSil Medical's EBITDA per Share for the six months ended in Dec. 2025 was A$-0.24.

OncoSil Medical YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for OncoSil Medical's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSil Medical YoY EBITDA Growth Chart

OncoSil Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -99.84 -13.69 13.51 40.50 38.01

OncoSil Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.52 52.59 42.77 31.74 66.67
ASX:OSL
40GF Score
OncoSil Medical Ltd ASX:OSL
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoSil Medical YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

OncoSil Medical's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(-1.37--2.21)/ | -2.21 |
=38.01 %

OncoSil Medical's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(-0.24--0.72)/ | -0.72 |
=66.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 66.67% mean?
OncoSil Medical (ASX:OSL) has a YoY EBITDA Growth of 66.67% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for OncoSil Medical and its competitors.
Is OncoSil Medical's YoY EBITDA Growth too high?
OncoSil Medical's current YoY EBITDA Growth is 66.67%. Overall, OncoSil Medical has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's YoY EBITDA Growth compare to ABT and SYK?
OncoSil Medical's YoY EBITDA Growth of 66.67% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for OncoSil Medical and its competitors. OncoSil Medical's current YoY EBITDA Growth is 66.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.91, compared to a current price of A$1.11 — trading 61.9% below its estimated fair value. The current YoY EBITDA Growth is 66.67%. OncoSil Medical's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current YoY EBITDA Growth is 66.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoSil Medical (ASX:OSL) Overvalued in 2026?

Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued. The current stock price of A$1.11 is trading 61.9% below its estimated GF Value™ of A$2.91. GuruFocus considers OncoSil Medical to be Possible Value Trap.

Key valuation signals for ASX:OSL:

  • YoY EBITDA Growth: 66.67%
  • GF Value™: A$2.91 vs. price of A$1.11 (61.9% below fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OncoSil Medical Business Description

Address 7 Eden Park Drive, Level 5, Macquarie Park, Sydney, NSW, AUS, 2113
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
40GF Score

Get the complete analysis for ASX:OSL

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.11
Price
A$2.91
GF Value